Aptahem enters into production agreement with BioSpring


    Aptahem AB (publ) can announce today that it has entered into a production agreement with BioSpring, a world-leading producer of oligonucleotides. BioSpring has been contracted to manufacture the substance in drug candidate Apta-1 for the company’s preclinical and upcoming...

    Read More

    Apta-1 improves survival rate and blood circulation in a clinical model relevant for sepsis


    Aptahem (publ) can today announce a positive outcome from a study performed in collaboration with Hooke Laboratories (US). The study evaluated the pharmaceutical candidate Apta-1 in a clinically relevant model for sepsis which showed a significant improvement in survival...

    Read More

    Aptahem adjusts the schedule and capital requirements as a result of the decision to update the clinical development strategy


    Aptahem’s preclinical programme is proceeding with the gradual collection of data on the Apta-1 effect profile, while the work on the company’s clinical development is proceeding in consultation with external experts. Dialogue with opinion leaders and potential partners has...

    Read More

    Aptahem strengthens its research and development organisation with industrial expertise in cardiovascular diseases and clinical development


    Aptahem can today announce that it has entered into an agreement with lecturer and registered practitioner Anders Bylock, a well-known expert on issues related to cardiovascular treatment including pre-clinical development, clinical trials and regulatory submissions. Dr Bylock will provide...

    Read More

    Drug News publish updates from Aptahem


    QuintilesIMS publish updates from Aptahem in their newsletter Drug News in December 2016 (see page 15). Aptahem’s CEO Mikael Lindstam presented the information at Bio Europe in Cologne in November 2016. Open Drug News For further information: Mikael Lindstam,...

    Read More

    Article about aptamers published in a scientific journal


    In November 2016 Smith & Franklin published an article about aptamer. Read the article. For further information: Mikael Lindstam, CEO Aptahem AB Tel: + 46 (0)766-33 36 99 E-mail: About Aptahem Aptahem is developing drug candidates for the...

    Read More

    Preclinical studies suggest great potential for Aptahems drug candidate Apta-1


    Aptahem, together with its US partner Hooke Laboratories in Boston, conducted preclinical studies on the anti-inflammatory effects of the drug candidate Apta-1 compared with Dexamethasone, one of the worldwide most prescribed drugs for inflammatory diseases. The studies indicate a...

    Read More

    New studies show APTA-1 has positive affect on key factors related to blood coagulation


    Aptahem announce that the results from studies carried out over recent months’, in a series of targeted animal studies, show that its lead compound APTA-1 demonstrates a positive effect on a number of key features related to the coagulation...

    Read More

    Aptahem starts close collaboration with leading research groups at the Nencki Institute in Warsaw


    Aptahem today announced that an extensive collaboration has begun with the Nencki Institute of Experimental Biology. Aptahem and various expert groups within the Institute will jointly examine the effects of the company’s developmental drug candidate, APTA-1. The Nencki Institute...

    Read More

    Aptahem enter cooperation agreement with leading research institute in hematology


    Aptahem announce they have entered a cooperation agreement with the Institute of Hematology and Blood Transfusion in Warsaw (IHIT), to identify APTA-1’s inhibitory mechanisms in the coagulation system. IHIT is Poland’s most prestigious hematology research institute and reference hospital....

    Read More